Literature DB >> 35603125

Pattern of molecular mimicry between spike protein of SARS CoV2 and human thrombopoietin in beta, delta and omicron variants: a basic pathophysiological process of COVID-19 related thrombocytopenia.

Rujittika Mungmunpuntipantip1, Viroj Wiwanitkit2.   

Abstract

Thrombocytopenia is a possible problem in COVID-19. Hemorrhagic problem might be a result of thrombocytopenia in COVID-19. Due to the emergence of thrombocytopenia in COVID-19, the pathophysiology of thrombocytopenia in COVID-19 is currently a important topic in blood research. An important possible pathogenesis is the molecular mimicry. In variants of COVID-19, the change in spike might occur and the effect on molecular mimicry, which might further imply for association with thrombocytopenia. Specific study on this phenomenon can help better understand on the pathogenesis process of thrombocytopenia. In this study, the authors assessed the magnitude of molecular mimicry between the spike protein of SARS CoV2 and human thrombopoietin in wild type and important variants of COVID-19. In this work, the authors used a molecular similarity analysis to assess the impact of mutations in delta and delta plus variations. Each variant has a decreased similarity score and the omicron variant has the least similarity score. In this study, the decreased similarity score in the variant can imply decreased mimicry phenomenon. Hence, it can imply that there will be decreased COVID-19 thrombocytopenia problem in the variant. AJBR
Copyright © 2022.

Entities:  

Keywords:  COVID-19; mimicry; thrombocytopenia

Year:  2022        PMID: 35603125      PMCID: PMC9123410     

Source DB:  PubMed          Journal:  Am J Blood Res        ISSN: 2160-1992


  18 in total

1.  Fast-spreading COVID variant can elude immune responses.

Authors:  Ewen Callaway
Journal:  Nature       Date:  2021-01-21       Impact factor: 49.962

2.  Beta-thalassemia may protect against COVID 19.

Authors:  Emmanuel Drouin
Journal:  Med Hypotheses       Date:  2020-06-28       Impact factor: 1.538

3.  COVID-19: beta-thalassemia subjects immunised?

Authors:  Edouard Lansiaux; Philippe Pierre Pébaÿ; Jean-Laurent Picard; Joachim Son-Forget
Journal:  Med Hypotheses       Date:  2020-05-12       Impact factor: 1.538

4.  Hemorrhagic Problem Among the Patients With COVID-19: Clinical Summary of 41 Thai Infected Patients.

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

5.  Cerebral venous thrombosis: A typical presentation of COVID-19 in the young.

Authors:  David E Klein; Richard Libman; Claudia Kirsch; Rohan Arora
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-05-23       Impact factor: 2.136

6.  Using bioinformatic protein sequence similarity to investigate if SARS CoV-2 infection could cause an ocular autoimmune inflammatory reactions?

Authors:  Işıl Kutlutürk Karagöz; Marion R Munk; Mücahit Kaya; René Rückert; Mustafa Yıldırım; Levent Karabaş
Journal:  Exp Eye Res       Date:  2021-01-02       Impact factor: 3.467

7.  New COVID-19 Variant, VUI-202012/01: Molecular Change, Epitope Alteration, and Implication for Vaccine Efficacy.

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  Int J Prev Med       Date:  2021-12-14

8.  Platelet proteome and function in X-linked thrombocytopenia with thalassemia and <i>in silico</i> comparisons with gray platelet syndrome.

Authors:  Daniel Bergemalm; Sofia Ramström; Caroline Kardeby; Kjell Hultenby; Anna Göthlin Eremo; Carina Sihlbom; Jörgen Bergström; Jan Palmblad; Maria Åström
Journal:  Haematologica       Date:  2020-09-28       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.